NTLA Stock: Buy or Sell? Price Target & Forecast

NTLA Intellia Therapeutics Inc As of Jul 16, 2026

$11.94

Clinical-stage CRISPR play down 58% YTD; positive Phase 3 data offset by burn rate and commercialization doubts.

Setup: Recovery / Speculative Confidence: 45 Horizon: 6-12 months Risk: Very High Category: Biotech – Early-stage / Clinical

🔒 Trade Plan — entry · target · stop

Entry Zone

$•••–•••

Target

$•••

Stop Loss

$•••

Risk / Reward

•.• : 1

Unlock the exact levels — free →

A free account reveals NTLA's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

Phase 3 Lonvo Z success (NTLA001 in ATTR-CM) may validate CRISPR in vivo approach. If regulatory path clears, first-in-class gene-edit asset could command premium valuation. Insider buys (31 vs 19 sells) suggest conviction. Cash position ($5.1B equiv. market cap / strong current ratio 5.08) funds runway into 2025+.

▼ Bear Case

Massive burn (-651% op margin, -610% net margin). P/S 26.97x unsustainable for pre-revenue biotech. Commercialization unproven; gene therapy has failed before. Wedbush neutral ($17 PT vs $11.94 now) despite positive data. Short-term sentiment soured ('overvalued', 'little commercial potential' headlines). Binary risk: approval or bust.

Valuation

Overvalued on traditional metrics; fair/undervalued IF clinical/commercial risk priced fairly — score 35/100

P/S 26.97x is absurd for a pre-revenue, cash-burning biotech. EV/EBITDA –3.04x (negative EBITDA) is meaningless. P/B 1.55x suggests tangible book value of ~$5.77/share retains some floor. Only justifiable if NTLA001 approval odds >40% and blockbuster peak sales >$500M. Few biotech comps command P/S >15x pre-launch.

Technical Levels

Support · $7.95 (52-week low / capitulation zone) · $10.50 (Recent bounce floor (1-2 weeks)) · $11.79 (Today's low)

Resistance · $12.70 (Today's high / near-term ceiling) · $14.50 (200-day moving average proxy (not supplied)) · $17.00 (Wedbush price target) · $28.25 (52-week high / bull-case breakout)

RSI: Not supplied

Financial Health

Score 65/100. Liquidity fortress (current ratio 5.08, quick ratio 4.42) provides breathing room through late-stage trials and potential FDA submission. No material debt disclosed. Burn is the watch — if NTLA001 approval path lengthens or trial delays occur, cash runway shortens; dilutive financing likely. Not in distress now, but binary on clinical success.

Catalysts

NTLA001 Phase 3 ATTR-CM enrollment completion / data readout extension	2024–2025	High — durability and safety profile extension will confirm or refute long-term gene-edit viability. Positive = $20+; negative = sub-$10.
FDA breakthrough therapy / fast-track designation decision	Next 6 months (likely)	Medium–High — accelerates path to BLA; signals regulatory confidence. Implied $15–18 re-rating.
Strategic partnership / co-development deal announcement	2024–2025	High — pharma backing reduces commercial risk, validates business model. Deal details (upfront $, milestones) will set tone for valuation.
Competing ATTR-CM therapies (Ionis, AZ, others) clinical/regulatory milestones	2024–2025	Medium — if competitors show superior durability or tolerability, NTLA001 advantage eroded.
Cash burn / quarterly cash position updates	Quarterly	Medium — if burn accelerates or runway tightens, dilution risk and stock downside pressure increase.

Risk Flags

Clinical-stage biotech: regulatory approval binary event. Single-asset pipeline (NTLA001 primary focus). Phase 3 positive, but EMA/FDA path uncertain.

Valuation divorced from fundamentals. Negative margins unsustainable. P/S 26.97x implies market pricing in blockbuster multi-indication scenario.

Commercialization unproven. In vivo CRISPR gene edits have never been commercialized at scale. Manufacturing, durability, off-target effects remain open questions.

Sentiment reversing. Despite Lonvo Z win, short-term selling pressure; negative ThinkTank pieces emerging. Stock near 52-week low ($7.95) — capitulation risk or value trap unclear.

Insider activity mixed signal. Net buys (31:19, +1M shares bought) suggest confidence, but not conclusive in biotech where insiders often wrong-footed.

See NTLA's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock NTLA free →

More Analyses

NVDA

AAPL

TSLA

MSFT

AMZN

GOOGL

NTLA FAQ

Is NTLA a buy right now?

Intellia Therapeutics Inc's current read is a Recovery / Speculative setup with 45 confidence over a 6-12 months horizon. Valuation: Overvalued on traditional metrics; fair/undervalued IF clinical/commercial risk priced fairly. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Is NTLA overvalued?

Overvalued on traditional metrics; fair/undervalued IF clinical/commercial risk priced fairly (valuation score 35/100). P/S 26.97x is absurd for a pre-revenue, cash-burning biotech. EV/EBITDA –3.04x (negative EBITDA) is meaningless. P/B 1.55x suggests tangible book value of ~$5.77/share retains some floor. Only justifiable if NTLA001 approval odds >40% and blockbuster peak sales >$500M. Few biotech comps command P/S >15x pre-launch.

What are the risks of buying NTLA?